Bristol-Myers Squibb BMY Noncontrolling interests in subsidiaries
Noncontrolling interests in subsidiaries at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's noncontrolling interests in subsidiaries.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's noncontrolling interests in subsidiaries?
- Bristol-Myers Squibb (BMY) reported noncontrolling interests in subsidiaries of $34M in Q1 2026.
- How has Bristol-Myers Squibb's noncontrolling interests in subsidiaries changed year-over-year?
- Bristol-Myers Squibb's noncontrolling interests in subsidiaries decreased by 42.4% year-over-year, from $59M to $34M.
- What is the long-term trend for Bristol-Myers Squibb's noncontrolling interests in subsidiaries?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's noncontrolling interests in subsidiaries has grown at a -11.3% compound annual growth rate (CAGR), from $60M to $33M.
- What does noncontrolling interests in subsidiaries mean?
- The portion of a subsidiary's equity owned by outside shareholders rather than the parent company.
- How do you interpret noncontrolling interests in subsidiaries?
- An increase suggests the company has consolidated more entities where it holds a majority but not total ownership, while a decrease may indicate buyouts of minority stakes or divestitures.
- How does noncontrolling interests in subsidiaries compare across companies?
- Common in large pharmaceutical firms with complex joint ventures or partially owned biotech subsidiaries; peers typically report this as non-controlling interest.